14DO
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
1414 Degrees Limited - Option Expiring 21-Aug-2020
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in 14DO
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in 14DO
N/A
14DO investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in 14DO also invest in...
Want more shares? Try these...
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The firm's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. The company is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. The company co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.
🙌 Performance (5Yr p.a)
-16.25%
📊 Share price
$0.01 AUD
🧬 BIOTECHNOLOGY
1414 Degrees Ltd. engages in the development, design, and manufacture of thermal energy storage systems. SiBox delivers high temperature carbon free industrial heat by harnessing the extremely high latent heat capacity of silicon. This enables intermittent renewables to provide flexible, ultra-high temperature heat 24/7 for industrial applications and to deliver reliable heat and power supply when required. The company is envisaged that the flexibility of the SiBox modular development concept provides a decarbonization pathway for energy users, such as high temperature industrial customers, mineral processing industries, thermal power stations and those needing a combined heat and power solution. The company is also developing the Aurora Energy Project located near Port Augusta, South Australia. The focus of the project is to develop a hybrid renewable energy project delivering reliable electricity to the region and national electricity market.